Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
| العنوان: | Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors |
|---|---|
| المؤلفون: | Félix López Cadenas, Laura Mezquita, María A Amores Martín, Roberto A. Escala-Cornejo, Luis Figuero-Pérez, Juan Jesús Cruz Hernández, Felipe Gómez-Caminero López, María Del Rosario Vidal Tocino, Alejandro Olivares-Hernández, Lorena Bellido Hernández |
| المصدر: | Case Reports in Oncological Medicine Case Reports in Oncological Medicine, Vol 2021 (2021) |
| بيانات النشر: | Hindawi Limited, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_treatment, Case Report, Ipilimumab, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, medicine, RC254-282, business.industry, Melanoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunotherapy, medicine.disease, medicine.anatomical_structure, Oncology, chemistry, 030220 oncology & carcinogenesis, Interleukin-6 receptor, Immunology, Bone marrow, Hemophagocytosis, Cytokine storm, business, 030215 immunology, medicine.drug |
| الوصف: | Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We present a case of hematological toxicity, manifested as hemophagocytic syndrome (HPS), which was successfully treated with an anti-interleukin-6 antibody (tocilizumab). Case Report. This case presents a 75-year-old woman diagnosed with metastatic choroidal melanoma, refractory to several lines of treatment. After the failure of the previous lines, ipilimumab was started. After the third dose, she developed grade 2 thrombocytopenia and anemia accompanied by elevated levels of ferritin, triglycerides, and decreased fibrinogen. Hemophagocytosis was observed in the bone marrow biopsy, and a PET-CT showed splenomegaly with increased metabolism. Treatment was based on high doses of corticosteroids and tocilizumab. Four days after the start of treatment, progressive clinical and analytical improvement was observed, achieving total remission of the condition. Discussion. HPS induced by immunotherapy is due to an immunorelated cytokine storm syndrome (CSS). The administration of the anti-interleukin-6 receptor antibody drug acted on this cytokine cascade, leading to stabilization and subsequent remission. For this reason, the use of tocilizumab should be part of the immunotherapy-induced HPS treatment algorithm. |
| تدمد: | 2090-6714 2090-6706 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f24bcca54d27c85e7c4133643d12ec72 https://doi.org/10.1155/2021/6631859 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....f24bcca54d27c85e7c4133643d12ec72 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20906714 20906706 |
|---|